Use of a receptor-type kinase modulator for treating polycystic kidney disease
The invention comprises a method of treating polycystic kidney disease (PKD) in a mammal, such as a human or feline (e.g., Persian cat), comprising administering a therapeutically effective amount of the compound of formula to the mammal. Also provided are uses of the compound for preparation of a medicament for treating PKD and the above compound and compositions comprising it for treating PKD.
1. A method of treating polycystic kidney disease (PKD) in a mammal, the method comprising administering a therapeutically effective amount of a compound of formula
or a pharmaceutically acceptable salt thereof, to a mammal having PKD,
wherein the administering of the compound or pharmaceutically acceptable salt thereof is by way of a tablet or liquid dosage form.
2. The method of claim 1 wherein the dosage form is a tablet.
3. The method of claim 2 wherein the compound or pharmaceutically acceptable salt thereof is 50 wt % of the tablet.
4. The method of claim 2 wherein the tablet comprises 50 mg of the compound or pharmaceutically acceptable salt thereof.
5. The method of claim 4 wherein the compound or pharmaceutically acceptable salt thereof is 50 wt % of the tablet.
6. The method of claim 2 wherein the mammal is a human.
7. The method of claim 2 wherein the mammal is a feline.
8. The method of claim 7 wherein the feline is a Persian cat.
9. The method of claim 2 wherein the mammal is a human.
10. The method of claim 2 wherein the mammal is a feline.
11. The method of claim 10 wherein the feline is a Persian cat.
12. The method of claim 4 wherein the mammal is a human.
13. The method of claim 5 wherein the mammal is a human.
14. The method of claim 2 wherein the tablet comprises the following components and amounts:
Component
Amount (% w/w)
the compound or pharmaceutically
50.00
acceptable salt thereof
Lactose Monohydrate
25.70
Microcrystalline Cellulose
10.00
Hypromellose
3.00
Crospovidone
7.00
Sodium Lauryl Sulfate
3.00
Colloidal Silicon Dioxide
0.70
Magnesium Stearate
0.60.
15. The method of claim 14 wherein the tablet comprises 50 mg of the compound or pharmaceutically acceptable salt thereof and the mammal is a human.
16. The method according to claim 2 wherein the administration is once daily.
17. The method according to claim 7 wherein the administration is once daily.
18. The method according to claim 12 wherein the administration is once daily.
19. The method according to claim 13 wherein the administration is once daily.
20. The method according to claim 14 wherein the administration is once daily.
21. The method according to claim 15 wherein the administration is once daily.
22. The method according to claim 1 wherein the dosage form is a liquid.
23. The method according to claim 22 wherein the liquid dosage form is a water-based solution.
24. The method according to claim 23 wherein the formulation is administered in an amount of 0.3 to 6 mg of the compound to kg of the mammal.
25. The method of claim 24 wherein the mammal is a human.
26. The method of claim 24 wherein the mammal is a feline.
27. The method of claim 25 wherein the feline is a Persian cat.